Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea. ...

Core Viewpoint - Nuwellis, Inc. has announced a securities purchase agreement for a private placement of shares and warrants, aiming to raise approximately $5 million to support its operations in precision cardiorenal care [1][3]. Group 1: Private Placement Details - The company will sell 994,537 shares of common stock at an effective offering price of $3.09 per share, along with warrants to purchase 1,989,074 additional shares [1]. - The warrants will have an exercise price of $2.84 per share, exercisable immediately upon issuance, and will expire five years after a resale registration statement becomes effective [1]. Group 2: Warrant Inducement Agreement - Nuwellis has entered into a warrant inducement agreement with an investor to immediately exercise certain existing warrants at a reduced exercise price of $3.09, allowing the purchase of 623,585 shares [2]. - In exchange for the immediate exercise, the company will issue new unregistered warrants for an additional 1,247,170 shares at the same exercise price of $2.84, also expiring five years after the effective registration statement [2]. Group 3: Financial Proceeds and Closing - The gross proceeds from both the private placement and the warrant inducement are expected to be around $5 million before deducting fees and expenses, with the closing anticipated on or about January 30, 2026 [3]. - Ladenburg Thalmann & Co. Inc. is acting as the sole placement agent for these transactions [3]. Group 4: Company Overview - Nuwellis, Inc. is focused on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring and therapy [6]. - The company is headquartered in Minneapolis, Minnesota, and aims to support clinical decision-making across various care settings [6][7]. Group 5: Product Information - The Aquadex SmartFlow system is a key product that provides therapy for patients with hypervolemia, indicated for both temporary and extended use in specific patient populations [9].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].

New York, New York--(Newsfile Corp. - January 29, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfala ...

Q2 FY26 Earnings January 29, 2026 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial ...

Core Viewpoint - CVRx, Inc. is set to release its fourth quarter 2025 financial and operating results on February 12, 2026, after market close, followed by a conference call to discuss the results [1]. Company Overview - CVRx, Inc. is a commercial-stage medical device company that specializes in developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3]. - The company's flagship product, Barostim™, is the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients [3]. - Barostim is an implantable device that sends electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3]. - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation (MDR) and holding CE Mark for heart failure and resistant hypertension in the European Economic Area [3].

Core Insights - Johnson & Johnson (JNJ) is recognized as a Dividend King, having consistently paid and increased dividends for over 50 years, making it a stable investment option during market volatility [1] - JNJ stock outperformed the market with a 43.7% increase last year, compared to the market's overall gain of 16.6%, and has continued to rise by over 10% in early 2026 [2] Business Structure and Performance - In 2023, JNJ spun off its consumer division into a separate company called Kenvue (KVUE), allowing JNJ to focus on a pure-play health care innovation business centered on drugs and medical devices [4] - The Innovative Medicine segment is the primary revenue driver, generating $15.7 billion in Q4 2023, a 10% year-over-year increase, and $60.4 billion for the full year, reflecting a 6% increase [4] - JNJ reported a 5.3% increase in worldwide sales to $94.2 billion, despite challenges from the loss of exclusivity on Stelara, with adjusted diluted earnings per share rising 8.1% to $10.79 [4] Growth Prospects - Oncology is projected to achieve 21% operational sales growth in 2025, with anticipated annual sales exceeding $50 billion by 2030, marking it as a significant growth engine for the company [5] - The MedTech segment also showed strong performance, with a 7.5% revenue growth in Q4 and 6.1% for the full year, generating $34 billion in sales, driven by advancements in Cardiovascular, Surgery, and Vision [5] - JNJ's MedTech division is supported by over 60 active clinical trials and multiple regulatory submissions planned, positioning it as a key growth pillar alongside Pharmaceuticals [5][6]

TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company’s fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. S ...

Core Insights - Stryker reported strong financial results for Q4 and the full year of 2025, achieving double-digit sales growth and adjusted earnings per share growth, with a notable operating margin expansion for the second consecutive year [2][6][12]. Q4 Results - Consolidated net sales for Q4 reached $7.2 billion, reflecting an 11.4% increase, with organic net sales growing by 11.0% [3][12]. - MedSurg and Neurotechnology segment net sales were $4.6 billion, up 17.5%, while Orthopaedics segment net sales increased by 2.2% to $2.6 billion [4][5]. - Adjusted net earnings for Q4 were $1.7 billion, marking an 11.6% increase, with adjusted earnings per diluted share rising to $4.47, a 11.5% increase [6][12]. Full Year Results - Total net sales for 2025 were $25.1 billion, an 11.2% increase from the previous year, with organic net sales growing by 10.3% [3][12]. - MedSurg and Neurotechnology segment net sales for the full year were $15.6 billion, up 15.7%, while Orthopaedics segment net sales increased by 4.3% to $9.5 billion [4][5]. - Reported net earnings for the full year were $3.2 billion, an 8.5% increase, with earnings per diluted share at $8.40, up 8.2% [6][12]. Earnings Analysis - Reported gross profit margin for Q4 was 64.5%, while the full year margin was 64.0% [6][12]. - Adjusted operating income margin increased by 100 basis points to 30.2% for Q4 and 26.3% for the full year [6][12]. - The company experienced a significant increase in operating income, with Q4 operating income at $1.8 billion, a 210.5% increase [6][12]. 2026 Outlook - Stryker anticipates organic net sales growth for 2026 to be in the range of 8.0% to 9.5%, with adjusted net earnings per diluted share expected to be between $14.90 and $15.10 [7]. - The company expects a modestly favorable pricing impact and a slight positive effect from foreign exchange rates on sales and earnings [7]. Sales Growth Analysis - The U.S. market contributed significantly to sales, with Q4 sales of $5.4 billion, an 11.7% increase, and full year sales of $19.0 billion, a 12.2% increase [24]. - International sales for Q4 were $1.7 billion, up 10.6%, and full year international sales reached $6.1 billion, an 8.1% increase [24]. Segment Performance - In the MedSurg and Neurotechnology segment, instruments sales increased by 17.1% in Q4, while vascular sales surged by 58.1% [26]. - Orthopaedics segment saw knee sales grow by 8.9% and hip sales by 8.1% in Q4 [26]. Financial Position - As of December 31, 2025, total assets were $47.8 billion, up from $43.0 billion in 2024, with cash and cash equivalents at $4.0 billion [19][20]. - Total liabilities increased to $25.4 billion, with long-term debt at $14.9 billion [20]. Cash Flow Analysis - Net cash provided by operating activities for 2025 was $5.0 billion, compared to $4.2 billion in 2024 [22]. - The company invested $4.9 billion in acquisitions, net of cash acquired, indicating a strong focus on growth through strategic investments [22].

Core Insights - Resmed reported strong financial results for the quarter ended December 31, 2025, with an 11% year-over-year revenue growth, driven by high demand for sleep and respiratory care devices and the expansion of its digital health ecosystem [3][5][21]. Financial Performance - Revenue for the quarter reached $1.422 billion, an increase of 11% compared to $1.282 billion in the same quarter of the previous year, with a 9% increase on a constant currency basis [4][5][21]. - Gross margin improved by 320 basis points to 61.8%, while non-GAAP gross margin increased by 310 basis points to 62.3%, attributed to manufacturing efficiencies and cost improvements [5][8][21]. - Income from operations rose by 18% to $491.7 million, with non-GAAP income from operations increasing by 19% to $517.2 million [4][5][21]. - Net income for the quarter was $392.6 million, a 14% increase from $344.6 million, with non-GAAP net income rising by 15% to $411.5 million [5][20]. - Diluted earnings per share increased by 15% to $2.68, while non-GAAP diluted earnings per share rose by 16% to $2.81 [5][20]. Operational Highlights - The company continues to invest in innovation to enhance its digital health capabilities and expand access to care [4][8]. - Operating cash flow for the quarter was $340 million, reflecting strong operational performance [5][17]. - Resmed declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026 [8][9]. Market Performance - Revenue growth was driven by a 11% increase in the U.S., Canada, and Latin America, while Europe, Asia, and other markets saw a 6% growth on a constant currency basis [8][21]. - The company reported a 5% increase in Residential Care Software revenue on a constant currency basis [8][21]. Strategic Initiatives - Resmed received FDA clearance for an AI-enabled digital medical device aimed at personalizing CPAP comfort settings, enhancing patient adherence [8]. - The company presented its long-term growth opportunities and leadership in digital sleep and respiratory health at the J.P. Morgan Healthcare Conference [8].